Oral Absorption of Peptides: The Effect of Absorption Site and Enzyme Inhibition on the Systemic Availability of Metkephamid
dc.contributor.author | Langguth, Peter | en_US |
dc.contributor.author | Amidon, Gordon L. | en_US |
dc.contributor.author | Merkle, Hans P. | en_US |
dc.date.accessioned | 2006-09-08T19:15:33Z | |
dc.date.available | 2006-09-08T19:15:33Z | |
dc.date.issued | 1994-04 | en_US |
dc.identifier.citation | Langguth, Peter; Merkle, Hans P.; Amidon, Gordon L.; (1994). "Oral Absorption of Peptides: The Effect of Absorption Site and Enzyme Inhibition on the Systemic Availability of Metkephamid." Pharmaceutical Research 11(4): 528-535. <http://hdl.handle.net/2027.42/41439> | en_US |
dc.identifier.issn | 0724-8741 | en_US |
dc.identifier.issn | 1573-904X | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/41439 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=8058610&dopt=citation | en_US |
dc.description.abstract | In this study the intestinal degradation and absorption of a synthetic pentapeptide, metkephamid, were investigated in the rat by determination of its wall permeabilities in the small and large intestine and the extent and mechanism of its intestinal degradation. The peptide was metabolized in the gut wall through contact with membrane-bound enzymes in the brush border membrane. The extent of metabolic inactivation depended on the intestinal segment investigated and decreased in the axial direction. No metabolism was found in the colon. The dimensionless wall permeabilities ( P w *), determined by single-pass perfusion, were also site dependent. P w * was highest in the ileum [1.91 ± 0.24, (SE); n = 4], followed by the jejunum (1.64 ± 0.34; n = 4) and the colon (0.67 ± 0.38; n = 4). Based on the permeability data alone and under the assumption of no presystemic metabolism, complete bioavailability would be predicted for metkephamid. However, following oral administration, the mean absolute bioavailability was only 0.22 ± 0.065% ( n = 3), indicating the overall dominance of degradation in the absorption process. Thus future strategies in oral peptide delivery should focus on increasing the stability of the peptide in the intestine by modifying the peptide structure and/or delivering the compound to an intestinal segment showing little or no enzymatic degradation. | en_US |
dc.format.extent | 1481362 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Kluwer Academic Publishers-Plenum Publishers; Plenum Publishing Corporation ; Springer Science+Business Media | en_US |
dc.subject.other | Biomedical Engineering | en_US |
dc.subject.other | Pharmacy | en_US |
dc.subject.other | Absorption | en_US |
dc.subject.other | Biomedicine | en_US |
dc.subject.other | Bioavailability | en_US |
dc.subject.other | Metkephamid | en_US |
dc.subject.other | Pharmacology/Toxicology | en_US |
dc.subject.other | Peptides | en_US |
dc.subject.other | Degradation | en_US |
dc.subject.other | Permeability | en_US |
dc.subject.other | Medical Law | en_US |
dc.subject.other | Biochemistry, General | en_US |
dc.title | Oral Absorption of Peptides: The Effect of Absorption Site and Enzyme Inhibition on the Systemic Availability of Metkephamid | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | College of Pharmacy, The University of Michigan, Ann Arbor, Michigan, 48109-1065 | en_US |
dc.contributor.affiliationum | ETH Department Pharmazie, Zürich, Switzerland; College of Pharmacy, The University of Michigan, Ann Arbor, Michigan, 48109-1065; ETH Department Pharmazie, Winterthurerstr. 190, CH-8057, Zürich, Switzerland | en_US |
dc.contributor.affiliationother | ETH Department Pharmazie, Zürich, Switzerland | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 8058610 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/41439/1/11095_2004_Article_304484.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1023/A:1018962415287 | en_US |
dc.identifier.source | Pharmaceutical Research | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.